Recent Finacing
Recent Raise
SuppreMol is a Martinsried/Munich biopharmaceutical company developing SM101, a recombinant soluble FcγRIIb for ITP and SLE, planning Phase IIa in SLE and advancing an anti‑FcγRIIb monoclonal antibody preclinically.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
